Decreases in the Serum VLDL-TG/Non-VLDL-TG Ratio from Early Stages of Chronic Hepatitis C: Alterations in TG-Rich Lipoprotein Levels
Open Access
- 25 February 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (2), e17309
- https://doi.org/10.1371/journal.pone.0017309
Abstract
The liver secretes very-low-density lipoproteins (VLDLs) and plays a key role in lipid metabolism. Plasma total triglyceride (TG) level variations have been studied in patients with hepatitis C virus (HCV)-related chronic hepatitis (CH-C). However, the results of these studies are variable. A homogenous assay protocol was recently proposed to directly measure the TG content in VLDL (VLDL-TG) and VLDL remnants. Using the assay protocol, we determined serum VLDL-TG levels in 69 fasting patients with biopsy-proven HCV-related chronic liver disease and 50 healthy subjects. Patients were classified into stages F0–F4 using the 5-point Desmet scale. Serum total TG levels in patients with non-cirrhotic (F1–F3) CH-C did not demonstrate significant differences compared with healthy subjects, but serum VLDL-TG levels did demonstrate significant differences. Mean serum VLDL-TG levels tended to decrease with disease progression from F1 to F4 (cirrhosis). Compared with healthy subjects, serum non-VLDL-TG levels significantly increased in patients with stages F2 and F3 CH-C; however, we observed no significant difference in patients with liver cirrhosis. Furthermore, the serum VLDL-TG/non-VLDL-TG ratio, when taken, demonstrated a significant decrease in patients with CH-C from the mildest stage F1 onward. The decrease in serum VLDL-TG levels was attenuated by increase in non-VLDL-TG levels in patients with non-cirrhotic CH-C, resulting in comparable total TG levels. Results of previous studies though variable, were confirmed to have a logical basis. The decrease in the serum VLDL-TG/non-VLDL-TG ratio as early as stage F1 demonstrated TG metabolic alterations in early stages of CH-C for the first time. The involvement of TG metabolism in CH-C pathogenesis has been established in experimental animals, while conventional TG measurements are generally considered as poor indicators of CH-C progression in clinical practice. The serum VLDL-TG/non-VLDL-TG ratio, which focuses on TG metabolic alterations, may be an early indicator of CH-C.This publication has 28 references indexed in Scilit:
- Metabolic profiles in patients with chronic hepatitis C: a case–control studyHepatology International, 2008
- Twenty‐four weeks of interferon α‐2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1Liver International, 2006
- Surfactant-Based Homogeneous Assay for the Measurement of Triglyceride Concentrations in VLDL and Intermediate-Density LipoproteinClinical Chemistry, 2005
- Serum lipid pattern in chronic hepatitis C: histological and virological correlationsJournal of Viral Hepatitis, 2005
- Characterization of a novel mutation causing hepatic lipase deficiency among French CanadiansJournal of Lipid Research, 2003
- Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: Relationship to abnormalities in high-density lipoproteinJournal of Hepatology, 1993
- Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Hydrolysis of human plasma high density lipoprotein2-phospholipids and triglycerides by hepatic lipaseBiochemical and Biophysical Research Communications, 1981
- Plasma lipids and lipoproteins in liver disease.Gut, 1978
- Secondary hypertriglyceridaemia in patients with parenchymal liver diseaseEuropean Journal of Clinical Investigation, 1977